Pegozafermin, a long-acting glycol-pegylated recombinant FGF21 analogue, effectively reduces liver fat and fibrosis in patients with severe hypertriglyceridemia, MASH, and liver fibrosis. Here, FGF21 is linked to Hepatic fibrosis.